- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-7089
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer ; volume:46 ; number:9 ; day:27 ; month:5 ; year:2019 ; pages:1919-1930 ; date:8.2019
European journal of nuclear medicine and molecular imaging ; 46, Heft 9 (27.5.2019), 1919-1930, 8.2019
- Creator
-
Müller, Cristina
Umbricht, Christoph A.
Gracheva, Nadezda
Tschan, Viviane J.
Pellegrini, Giovanni
Bernhardt, Peter
Zeevaart, Jan Rijn
Köster, Ulli
Schibli, Roger
Van der Meulen, Nicholas P.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-019-04345-0
- URN
-
urn:nbn:de:101:1-2019110609385182987058
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Müller, Cristina
- Umbricht, Christoph A.
- Gracheva, Nadezda
- Tschan, Viviane J.
- Pellegrini, Giovanni
- Bernhardt, Peter
- Zeevaart, Jan Rijn
- Köster, Ulli
- Schibli, Roger
- Van der Meulen, Nicholas P.
- SpringerLink (Online service)
Other Objects (12)
213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer - combination strategies
Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Targeted palliative radionuclide therapy for metastatic bone pain
S82. Proffered paper: In-vivo testing of PSMA-targeted T-cell immunotherapy for prostate cancer
Nanoparticles Targeted to Fibroblast Activation Protein Outperform PSMA for MRI Delineation of Primary Prostate Tumors
Effect of point-spread function reconstruction for indeterminate PSMA-RADS-3A lesions on PSMA-targeted PET imaging of men with prostate cancer
\(^18}\)F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging
213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer - combination strategies
Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Targeted palliative radionuclide therapy for metastatic bone pain
S82. Proffered paper: In-vivo testing of PSMA-targeted T-cell immunotherapy for prostate cancer
Nanoparticles Targeted to Fibroblast Activation Protein Outperform PSMA for MRI Delineation of Primary Prostate Tumors
Effect of point-spread function reconstruction for indeterminate PSMA-RADS-3A lesions on PSMA-targeted PET imaging of men with prostate cancer
\(^18}\)F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging
213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer - combination strategies
Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer
Combination therapies to enhance the efficacy of PSMA-targeted radioligand therapy in prostate cancer
Targeted palliative radionuclide therapy for metastatic bone pain
S82. Proffered paper: In-vivo testing of PSMA-targeted T-cell immunotherapy for prostate cancer
Nanoparticles Targeted to Fibroblast Activation Protein Outperform PSMA for MRI Delineation of Primary Prostate Tumors
Effect of point-spread function reconstruction for indeterminate PSMA-RADS-3A lesions on PSMA-targeted PET imaging of men with prostate cancer